Early treatment with BMMSC for spinal cord injury results in long-term benefits

The earlier, the better: in spinal cord injuries, treatment with mesenchymal stem cells may make a difference if applied soon after trauma. In this 2015 Polish case report, a 15 year old girl was treated with bone marrow MSC just 21 days after injury. She was paraplegic at the start of treatment (able to move her arms, but no control over trunk, legs, or bowels). She received 154 million BMMSC, spaced over every 3-4 months over the course of 2 years. At the end of treatment, the patient was able to stand, regained control over her trunk and sensation in her legs and bowels.

Cell Transplant. 2015;24(4):661-72. doi: 10.3727/096368915X687796. Epub 2015 Mar 24.

Continuous improvement after multiple mesenchymal stem cell transplantations in a patient with complete spinal cord injury.

Jarocha D, Milczarek O, Wedrychowicz A, Kwiatkowski S, Majka M.


Interruption of spinal cord (SC) continuity leads to functional loss below the lesion level. The purpose of this study was to evaluate the safety and efficacy of bone marrow nucleated cell (BMNC) and multiple mesenchymal stem cell (MSC) transplantations in spinal cord injury (SCI). A patient with total SC interruption at the Th2-3 level underwent experimental therapy with BMNC and MSC transplantations followed with intensive neurorehabilitation treatment. At admission, 6 h after SCI, the patient was scored ASIA A, had a Th1 sensation level, paraplegia with sphincter palsy, and was without the ability to control trunk movement. Neurophysiology examination showed bilateral axonal damage to the motor and sensory neural fibers with no motor unit potentials or peripheral motor nerve conduction in the lower extremities. The standard therapy had been applied and had not produced any positive results. The patient was treated with autologous BMNCs injected intravenously (3.2×10(9)) and intrathecally (0.5×10(9)) 10 weeks after the SCI and with five rounds of MSCs every 3-4 months (1.3-3.65×10(7)) administered via lumbar puncture. Total number of transplanted MSC cells during the course of treatment was 1.54×10(8). There were no complications related to transplantations and no side effects related to the therapy during 2 years of treatment. The ASIA score improved from A to C/D (from 112 to 231 points). The sensation level expanded from Th1 to L3-4, and the patient’s ability to control the body trunk was fully restored. Bladder filling sensation, bladder control, and anal sensation were also restored. Muscle strength in the left lower extremities improved from plegia to deep paresis (1 on the Lovett scale). The patient’s ability to move lower extremities against gravity supported by the movements in quadriceps was restored. The patient gained the ability to stand in a standing frame and was able to walk with the support of hip and knee ortheses. Magnetic resonance imaging (MRI) revealed that at the Th2/Th3 level, where the hemorrhagic necrosis was initially observed, small tissue structures appeared. Our results suggest that repeated intrathecal infusions of MSCs might have the potential to produce clinically meaningful improvements for SCI patients.

PMID: 5807231

Take the first step towards the healthier life you deserve.